The Global Fund is making funds and flexibilities available to support countries to continue to deliver impact in existing grants, develop quality new grants for the next cycle and strengthen health systems while responding to COVID-19.

3 April 2020

 

COVID-19: Operational Update for Partners

The COVID-19 pandemic threatens health systems worldwide and will impact existing efforts to fight AIDS, tuberculosis and malaria.

The Global Fund is making funds and flexibilities available to support countries to continue to deliver impact in existing grants, develop quality new grants for the next cycle and strengthen health systems while responding to COVID-19.

This update outlines the flexibilities the Global Fund is introducing to its processes, as follows:

• Funding requests: New submission dates have been added so countries have more flexibility to present their funding requests and move to grant-making shortly after.
• Guidance Notes: Technical guidance is rapidly being developed in response to the new pandemic, its relationship to HIV, TB and malaria, and the implications for the Global Fund. The Global Fund strictly follows WHO guidelines. Internal guidance for the three diseases has been shared with Global Fund staff and currently available on the website.
• Supply Chain: The Global Fund is assessing potential delays for every single purchase order processed through its Pooled Procurement Mechanism (PPM). As of today, 9% of orders face delays of more than 30 days. By mid-April we will have visibility on deliveries expected in 2020, which will be helpful for mitigating delays and facilitating timely support to Principal Recipients.
  See available guidance for Principal Recipients.
• CCMs: engagement and transparency within funding request development and oversight of existing investments remain key areas of work to maintain during COVID-19. While eligibility requirements remain unchanged to ensure these core responsibilities of CCMs continue, flexibilities introduced include adapting funded activities to the COVID-19 response and reprogramming savings from reduced travel costs as agreed with your Country Team and the CCM Hub at the Secretariat.

Over the coming weeks, the Global Fund will issue further communications to partners on the following topics: disbursements, supply chain and procurement. Please visit our website for further updates.

 

Guidance on COVID-19

To fight COVID-19 and mitigate the impact this pandemic will have on programs to fight AIDS, TB and malaria in vulnerable contexts, the Global Fund is enabling countries to use up to 5% of approved grant funding to help protect and treat vulnerable communities.

Under the new guidelines, the Global Fund is encouraging countries to redeploy underutilized assets, repurpose grant savings and, in exceptional cases, reprogram funding from existing grants.

 

Revised Submission Windows for New Funding Requests

The Global Fund has introduced flexibilities for funding request submissions for Windows 2 and 3, allowing applicants to submit funding requests as soon as they are ready, and moving to grant-making shortly after. Technical Review Panel (TRP) Review and Recommendation Form will be delivered within 8-weeks of submission date. Applicants select submission dates that allow enough time to complete grant-making and prepare for implementation before the grant starts.

Window 2 submission dates:
Window 2a: 30 April
Window 2b: 31 May
Window 2c: 30 June

Window 3 submission dates:
Window 3a: 31 July
Window 3b: 31 Aug

Applicants currently registered for Window 2 will be automatically moved to 2b, and Window 3 to 3b. Global Fund Country Teams are responsible for adjusting registration, as needed.

More updates related to funding requests can be found in this Q&A.

 

Other Processes
– Delegation in the event of COVID-19-related absences. Internal processes at the Secretariat are being put in place to ensure back up of staff in case of illness, including all functions of Country Teams. A delegation approach and different contact points for your Country Team will be communicated in due time.

– Submission timelines and minimum requirements for completion and validation of defined Progress Updates and Disbursement Requests (PU and PUDRs or PU/DRs) are in place. The guidelines vary according to PU/DR deadlines, with extensions of up to 30 days for upcoming deadlines. For the PU/DRs with reporting periods ending March, April and June COVID-19 specific minimum reporting requirements are outlined in this document.

– CCMs can adapt activities funded by the CCM funding agreement to the COVID-19 emergency response. As CCMs are encouraged to strengthen remote participation and engagement, particularly from communities, and those living with the diseases, members are invited to opt for remote attendance to meetings, releasing savings to be reprogrammed from the reduced travel costs. Additional flexibilities on the use of CCM Funding can be discussed with the Global Fund Secretariat CCM Hub Focal Point and Country Team. For more information on CCM flexibilities and requirements check the Q&A which is being regularly updated with the latest guidance.

 

Health Product Supply

 

The product supply situation as a result of COVID-19 is rapidly evolving, affecting key materials and ingredients, finished health products and logistics As of 30 March 2020, the Global Fund’s product and delivery outlook shows the overall impact of COVID-19 on health product supply chains for Global Fund grants has increased to moderate.

Delivery delays of a few weeks or more are currently expected. The Global Fund is assessing potential delays for every single purchase order processed through its Pooled Procurement Mechanism (PPM). As of today, 9% of Pooled Procurement Mechanism orders face delays of more than 30 days. By mid-April will have visibility on deliveries expected in 2020, which will be helpful for mitigating delays and facilitating timely support to Principal Recipients.

All transport modes are impacted, and cost increases are expected. Rapid approval of freight estimates by Principal Recipients may permit securing the best currently available option, while approval delays may lead to missed shipping slot opportunities, further delays and cost increases.

Country Teams and Supply Operations are working with Principal Recipients to review mitigation plans, adjust delivery quantities and adapt lead times. All PRs are asked to submit requisitions and request forms by 10 April for all 2020 deliveries, both for PPM and non-PPM grants.
Customized labelling will no longer be accepted during this period.

Procuring Personal Protective Equipment and other COVID-19 emergency medical supplies. WHO has consolidated a list of COVID-19 critical items. Principal Recipients are strongly encouraged to source Personal Protective Equipment (PPE) and other emergency COVID-19-related medical supplies through national or regional channels as early as possible to minimize supply delays or disruptions.

Only if Principal Recipients face significant challenges sourcing PPE through local channels, should they reach out directly to UNICEF Procurement Services and order through their catalogue. UNICEF is best placed to provide support with expertise in emergency procurements and long term agreements with suppliers of these products.

Currently, Global Fund grant funds can be used to purchase emergency COVID-19 response products directly from UNICEF. Countries that decide to procure on their own can have the Global Fund make payments on their behalf by using a third-party payment mechanism.
Principal Recipients for TB programs may also source PPE products through the StopTB Partnership’s Global Drug Facility. There are severe global supply constraints for these products and Principal Recipients should expect normal or extended lead times when procuring through UNICEF or the Global Drug Facility.

Additional Information:

Health Product Supply updates can be found here.

COVID-19 Impact on Supply Chain Logistics: Assessment and Recommendations

– 30 March 2020

COVID-19 Procurement and Supply Update for Global Fund Principal Recipients

– 19 March 2020

Regular updates on the supply security situation for products and logistics are  here.

 

Resources for Applicants & Implementers

COVID-19 Situation Reports
COVID-19 on the Global Fund Website   
COVID-19 Q&A

Guidance Notes

Global Fund investments and advice to Principal Recipients and implementers strictly follow WHO guidelines. An aggregated list of partner COVID-19 technical guidance can be found on the Global Fund website.

The Global Fund Secretariat has also prepared internal guidance for its staff, which is being updated on a regular basis, informed by ongoing discussions with WHO and other key partners. An external version of these guidelines will be made available on the Global Fund website in the next week.

In the meantime, the following internal key messages are intended to support countries to operationalize WHO guidelines, adapting them to COVID-19 and country-specific contexts.

HIV

HIV investments should protect continuation of essential HIV services, focusing on treatment and prevention.

COVID-19 response should be in line with WHO guidance and the country specific situation.

Swift service adaptation and the increase of resources to civil society and communities to boost their capacity is encouraged.

Support multi-months- dispensing of ARVs to ensure people on treatment have the drugs they need while reducing the frequency of visits to health facilities. Include important consumables for prevention and treatment, such as condoms, ARVs for PrEP, methadone/ buprenorphine for Opioid Substitution Therapy, in adapted procurement plans. Support is available from Regional HPM managers; Supply Operations and HIV country focal points.

TB

Those living with TB are expected to be disproportionately impacted, as both TB and COVID-19 are respiratory conditions.

Preliminary reports from countries affected by Covid-19 have shown a sharp decline of TB notification and quality of services

Following FDA approval of COVID-19 test (Xpert® Xpress SARS-CoV-2) using GeneXpert machines used in TB programs, the Global Fund having discussions with the manufacturer and other stakeholders.

TB services can be impacted in diagnosis, treatment, prevention and at the health systems-level.

Malaria

Malaria control and elimination activities must continue, with modifications where appropriate, to avoid an upsurge in morbidity, mortality, and further stress on health systems.

The WHO urges countries to continue malaria services in the context of the COVID-19 pandemic.

Partners continue to develop guidance on how to conduct LLIN campaigns as safe as possible given the current context.

Forthcoming guidance covers case management, prevention, distribution, IPTp, Communication, M+E and cross cutting considerations.

RSSH

Balance the demands of the acute response to COVID-19 with the maintenance of essential health service delivery, including for HIV, TB and malaria.

Ensure decentralized and flexible financing so health facilities can respond more effectively to the local context.

Strengthen laboratory support systems as diagnostic testing is critical for tracking the virus, understanding epidemiology, informing case management and suppressing transmission.

Govern, equip, train, motivate and maintain the health workforce, with particular attention to community health workers.

Strengthen community systems to allow for effective communication, case detection and management, as well as establishing trust in health system.

 

Please feel free to forward this update to Principal Recipients, sub-recipients and other relevant in-country partners involved in Global Fund-related processes.

 

 

 

 

 

3 avril 2020

 

COVID-19 : informations opérationnelles destinées aux partenaires

La pandémie de COVID-19 menace les systèmes de santé dans le monde entier et aura une incidence sur les efforts actuellement déployés pour lutter contre le sida, la tuberculose et le paludisme.

Le Fonds mondial dégage des fonds et met en place des flexibilités afin d’aider les pays à préserver l’impact des programmes subventionnés en cours, à élaborer de nouveaux programmes de qualité pour le prochain cycle de financement et à renforcer les systèmes de santé, tout en ripostant à l’épidémie de COVID-19.

Ces informations opérationnelles actualisées présentent les flexibilités introduites par le Fonds mondial dans ses procédures :

• Demandes de financement. De nouvelles dates de soumission ont été ajoutées de manière à ce que les pays aient davantage de souplesse pour présenter leurs demandes de financement et passer rapidement à la phase d’établissement des subventions.
• Notes d’orientation. Des notes d’orientation sont en train d’être élaborées en réponse à la nouvelle pandémie, qui traitent notamment du rapport entre la lutte contre le VIH, la tuberculose et le paludisme et la lutte contre la COVID-19, et des conséquences de la pandémie pour le Fonds mondial. La note d’orientation concernant le paludisme est déjà disponible; les notes d’orientation portant sur le VIH et la tuberculose seront publiées prochainement.

Chaîne d’approvisionnement. Le Fonds mondial est en train d’estimer les retards éventuels pour chaque commande passée par l’intermédiaire du mécanisme d’achat groupé. À ce jour, 9 % des commandes subissent un retard de livraison de plus de 30 jours. À la mi-avril, nous aurons une meilleure vision des livraisons attendues en 2020, ce qui nous aidera pour limiter les retards et apporter un soutien rapide aux récipiendaires principaux.

Voir les recommandations disponibles destinées aux récipiendaires principaux

Instances de coordination nationale. La participation et la transparence dans l’élaboration des demandes de financement et dans le suivi des investissements en cours doivent être préservées en cette période de pandémie. Bien que les critères d’admissibilité demeurent inchangés afin d’assurer la poursuite de ces tâches essentielles par les ICN, les flexibilités mises en place permettent notamment d’adapter des activités financées à la situation sanitaire actuelle et de reprogrammer des économies réalisées sur les déplacements en accord avec votre équipe de pays et le pôle ICN au Secrétariat.

Dans les semaines à venir, le Fonds mondial publiera d’autres communications à l’intention des partenaires sur les sujets suivants : les décaissements, la chaîne d’approvisionnement et les achats. Rendez-vous sur notre site pour consulter les dernières informations actualisées.

 

Instructions concernant la pandémie de COVID-19

Pour lutter contre la COVID-19 et atténuer l’impact de cette pandémie sur les programmes de lutte contre le sida, la tuberculose et le paludisme dans des contextes de vulnérabilité, le Fonds mondial autorise les pays à utiliser jusqu’à 5 % du montant d’une subvention approuvée pour protéger et traiter des communautés vulnérables.

Dans le cadre de ces nouvelles directives, le Fonds mondial encourage les pays à redéployer des actifs sous-utilisés, à réorienter des économies réalisées sur une subvention et, dans des cas exceptionnels, à reprogrammer les fonds de subventions en cours.

 

Des périodes de présentation revues pour les nouvelles demandes de financement

Le Fonds mondial a mis en place des flexibilités concernant les périodes de présentation nº 2 et nº 3, qui permettent aux candidats de soumettre leurs demandes de financement dès que celles-ci sont prêtes et de passer rapidement à la phase d’établissement des subventions. Le formulaire d’examen et de recommandation du Comité technique d’examen des propositions sera transmis dans un délai de 8 semaines à compter de la date de présentation de la demande. Les candidats doivent choisir des dates de présentation qui leur laisseront suffisamment de temps pour terminer la phase d’établissement des subventions et se préparer en vue de la mise en œuvre avant la date de début des subventions.

Dates pour la période de présentation nº 2 :

Période 2a : 30 avril 2020
Période 2b : 31 mai 2020
Période 2c : 30 juin 2020

Dates pour la période de présentation nº 2 :

Période 3a : 31 juillet 2020
Période 3b : 31 août 2020

Les candidats actuellement inscrits pour les périodes de présentation nº 2 et nº 3 seront automatiquement déplacés vers les périodes 2b et 3b respectivement. Les équipe de pays du Fonds mondial sont chargées de procéder aux modifications nécessaires.
D’autres informations relatives aux demandes de financement sont données dans ces questions/réponses.

 

Autres procédures

Délégation en cas d’absence liée à la COVID-19. Des procédures internes au Secrétariat sont mises en place pour assurer le remplacement des personnels malades, notamment à tous les postes des équipes de pays. Les détails d’unedémarche de délégation et les coordonnées de plusieurs référents dans votre équipe de pays vous seront communiqués en temps voulu.

Un calendrier de remise ainsi que des exigences minimales pour la réalisation et la validation des rapports sur les résultats actuels/demande de décaissement (RA et RA/DD) ont été définis. Les instructions varient en fonction des délais, avec des extensions pouvant aller jusqu’à 30 jours pour les échéances à venir. Pour les rapports RA/DD dont la période de communication de l’information se termine en mars, en avril ou en mai, les informations minimales à rapporter concernant la COVID-19 sont précisées dans ce document.

Les instances de coordination nationale peuvent adapter les activités financées dans le cadre de leur accord de financement pour y intégrer des mesures d’urgence visant à lutter contre la pandémie. Alors que les ICN sont encouragées à favoriser une participation au dialogue à distance − en particulier pour les communautés et les personnes vivant avec les maladies −, leurs membres sont également invités à opter pour une participation à distance aux réunions, ce qui permettra de reprogrammer les économies réalisées sur les frais de déplacement. D’autres flexibilités concernant l’utilisation du financement des ICN peuvent être discutées avec le référent administratif du pôle ICN et l’équipe de pays au Secrétariat du Fonds mondial. Pour plus d’informations sur ces flexibilités et leurs conditions, reportez-vous à cesquestions/réponses qui seront régulièrement actualisées en fonction des dernières directives.

 

Approvisionnements en produits médicaux
La situation des approvisionnements en produits médicaux engendrée par la pandémie de COVID-19 évolue rapidement et concerne des matériels et des principes actifs essentiels, des produits finis médicaux et la chaîne logistique. Au 30 mars 2020, les perspectives du Fonds mondial concernant l’offre et les livraisons montrent un

impact accru de la pandémie de COVID‑19 sur les chaînes d’approvisionnement de produits médicaux

financés par des subventions du Fonds, impact désormais qualifié de modéré.

Il faut actuellement s’attendre à des délais de livraison de quelques semaines voire plus. Le Fonds mondial est en train d’estimer les retards éventuels pour chaque commande passée par l’intermédiaire du mécanisme d’achat groupé. À ce jour, 9 % de ces commandes subissent un retard de livraison de plus de 30 jours. À la mi-avril, nous aurons une meilleure vision des livraisons attendues en 2020, ce qui nous aidera pour limiter les retards et apporter un soutien rapide aux récipiendaires principaux.

Tous les modes de transport étant touchés, il faut s’attendre à une augmentation des coûts. Une approbation rapide du coût estimé du transport par les récipiendaires principaux pourra éventuellement permettre de sécuriser la meilleure option actuellement disponible. À l’inverse, des délais d’approbation trop longs pourront faire manquer des créneaux d’expédition, causer des retards supplémentaires et entraîner une augmentation des coûts.

En collaboration avec les récipiendaires principaux, les équipes de pays et le département des achats s’attachent à examiner des plans d’atténuation des risques, à ajuster les quantités à livrer et à adapter les délais de livraison. Il a été demandé à tous les récipiendaires principaux de soumettre leurs demandes d’achat − que celles-ci passent ou non par le mécanisme d’achat groupé − avant le 10 avril.
L’étiquetage personnalisé ne sera plus accepté durant cette période.

Achats d’équipements de protection individuelle et d’autres fournitures médicales nécessaires pour faire face à la pandémie. L’OMS a publié une liste de

matériel indispensable dans la lutte contre la COVID-19. Les récipiendaires principaux sont fortement encouragés à commander les équipements de protection individuelle (EPI) et autres fournitures médicales nécessaires pour faire face à la pandémie en passant par des circuits d’approvisionnement nationaux ou régionaux. Ces commandes devront être passées le plus vite possible afin de limiter les risques de retards ou de perturbations dans les approvisionnements.

Si des récipiendaires principaux rencontrent des problèmes importants pour acheter des EPI via des circuits d’approvisionnement locaux, et uniquement dans ce cas, ils pourront s’adresser directement aux services d’achat de l’UNICEF et utiliser lecatalogue de l’organisation pour passer leurs commandes. L’UNICEF est le mieux placé pour apporter une expertise dans les achats d’urgence et les accords à long terme avec les fournisseurs de ces produits.

Actuellement, il est possible d’utiliser des fonds provenant de subventions du Fonds mondial pour acheter directement auprès de l’UNICEF les produits nécessaires pour répondre à l’urgence de la pandémie de COVID-19. Les pays qui décident d’acheter ces produits par eux‑mêmes ont la possibilité de les faire payer en leur nom par le Fonds mondial en recourant à un mécanisme de tiers payeur.
Les récipiendaires principaux de subventions destinées à des programmes de lutte contre la tuberculose peuvent également s’approvisionner en équipements de protection individuelle auprès du

Service pharmaceutique mondial du partenariat Halte à la tuberculose

. En raison des fortes contraintes d’approvisionnement qui existent à l’échelle mondiale, les récipiendaires principaux devront prévoir des délais normaux ou plus longs s’ils achètent ces produits par l’intermédiaire de l’UNICEF ou du Service pharmaceutique mondial.

Informations complémentaires

Des informations actualisées sur les approvisionnements en produits médicaux sont disponibles ici.

Impact de la COVID-19 sur la logistique des chaînes d’approvisionnement : évaluation et recommendation

– 30 mars 2020

COVID-19 : informations actualisées concernant les achats et les approvisionnements pour les récipiendaires principaux des subventions du Fonds mondial

– 19 mars 2020

Des informations actualisées sur la situation en matière de sécurité des approvisionnements et de logistique sont disponibles ici.

 

Ressources pour les candidats et les maîtres d’œuvre

Rapports de situation COVID-19
La COVID-19 sur le site web du Fonds mondial
COVID-19 : questions/réponses

 

Notes d’orientation

Les investissements du Fonds mondial ainsi que les conseils donnés aux récipiendaires principaux et aux maîtres d’œuvre sont strictement conformes aux directives de l’OMS. Une liste complète des notes d’orientation techniques concernant la COVID-19 est disponible sur le site web du Fonds mondial.

Le Secrétariat du Fonds mondial a également élaboré des directives internes pour son personnel, qui sont régulièrement actualisées sur la base d’échanges permanents avec l’OMS et d’autres partenaires clés. Une version de ces lignes directrices destinée au personnel extérieur au Secrétariat sera mise en ligne la semaine prochaine sur le site web du Fonds mondial.

En attendant, les messages clés suivants sont destinés à aider les pays à mettre en œuvre les directives de l’OMS, en les adaptant à l’épidémie de COVID-19 et aux contextes nationaux.

VIH

• Les investissements dans la lutte contre le VIH doivent préserver la continuité des services essentiels, en particulier les services de traitement et de prévention.
• La riposte à la COVID-19 doit être menée selon les directives de l’OMS et en fonction de la situation particulière du pays.
• Une adaptation rapide des services et une augmentation des ressources visant à renforcer les capacités de la société civile et des communautés sont encouragées.
• Faciliter la dispensation d’antirétroviraux pour plusieurs mois afin de s’assurer que les personnes sous traitement disposent des médicaments dont elles ont besoin tout en réduisant la fréquence de leurs déplacements dans des établissements de santé. Inclure les consommables importants pour la prévention et le traitement − préservatifs, antirétroviraux pour la prophylaxie préexposition, méthadone/buprénorphine pour les traitements de substitution aux opiacés − dans des plans d’achat adaptés. Un appui pourra vous être apporté par les responsables régionaux de la gestion des produits de santé, le département des achats du Fonds mondial et les référents VIH dans le pays.

Tuberculose

On s’attend à ce que les personnes qui vivent avec la tuberculose soient particulièrement touchées par la pandémie dans la mesure où la tuberculose et la COVID-19 sont toutes deux des affections respiratoires.

Les premiers rapports en provenance de pays touchés par la COVID-19 font état d’une forte diminution du nombre de cas de tuberculose signalés et d’une baisse de qualité des services.

Suite à l’approbation par la FDA du test de dépistage (Xpert® Xpress SARS-CoV-2) effectué avec les machines GeneXpert utilisées dans le cadre des programmes de lutte contre la tuberculose, le Fonds mondial est en discussion avec le fabricant et d’autres parties prenantes.

Cela pourra avoir une incidence sur les services de dépistage, de traitement et de prévention de la tuberculose au niveau des systèmes de santé.

Paludisme

Les activités visant à contrôler et éliminer le paludisme doivent se poursuivre − avec quelques modifications au besoin − afin d’éviter que la morbidité et la mortalité n’augmentent soudainement et qu’une pression supplémentaire ne vienne s’exercer sur les systèmes de santé.

L’OMS exhorte les pays à assurer la continuité des services de lutte contre le paludisme dans le contexte de la pandémie de COVID-19.

Les partenaires continuent d’élaborer des instructions afin de pouvoir mener des campagnes de distribution de MILD dans les meilleures conditions de sécurité au vu du contexte actuel.

Certaines instructions portent plus spécifiquement sur la prise en charge des cas, la prévention, la distribution, les traitements préventifs intermittents pendant la grossesse, la communication, le suivi et l’évaluation, et certains aspects transversaux.

Systèmes résistants et pérennes pour la santé

Trouver un équilibre entre les besoins aigus liés à la pandémie de COVID-19 et la nécessité de maintenir la prestation de services de santé essentiels, notamment les services de lutte contre le VIH, la tuberculose et le paludisme.

Assurer un financement souple et décentralisé de manière à ce que les établissements de santé puissent répondre plus efficacement à la situation locale.

Renforcer les dispositifs de soutien aux laboratoires, dans la mesure où le dépistage est crucial pour suivre la propagation du virus, comprendre les aspects épidémiologiques de la maladie, orienter la prise en charge des cas et mettre fin à la transmission.

Diriger, équiper, former, motiver et maintenir les équipes soignantes, en prêtant une attention particulière aux agents de santé communautaires.

Renforcer les systèmes communautaires pour permettre une communication, une détection des cas et une prise en charge efficaces et pour instaurer une confiance dans le système de santé.

CCM Vietnam is calling for nominations for membership (term 2020 – 2022)

The Global Fund is an international financing institution that fights AIDS, tuberculosis and malaria with a 21st century approach: partnership, transparency, constant learning and results-based funding.

The Global Fund to fight AIDS, Tuberculosis and Malaria was created in 2002 to dramatically increase resources for the fight against the three pandemics. It spurs partnerships between government, civil society and the private sector and communities living with the diseases, the most effective way to fight these deadly infectious diseases. The Global Fund does not manage or implement programs on the ground, relying instead on local experts. It works with partners to ensure that funding serves the men, women and children affected by these diseases in the most effective way.

Country Coordinating Mechanisms (CCM) are central to the Global Fund’s commitment to local ownership and participatory decision-making. These country-level multi-stakeholder partnerships develop and submit grant proposals to the Global Fund based on priority needs at the national level. After grant approval, they oversee progress during implementation.

CCM include representatives from both the public and private sectors, including governments, multilateral and bilateral agencies, non-governmental organizations, academic institutions, private businesses and people living with diseases.

The CCM in Vietnam (VN-CCM) was established in 2004 following Decision No. 4557/QD-BYT issued by the Minister of Health; it has a broad mandate as a national coordinating body for AIDS, tuberculosis, malaria and VUSTA; the VN-CCM oversees the national response related to the three diseases and supports the coordination of all partners. VN-CCM builds on and is linked to existing mechanisms for planning at the national level and is consistent with national strategic plans. More information of the CCM Viet Nam can be found at: www.ccmvietnam.gov.vn

Membership in the CCM is broadly representative of a variety of stakeholders, each representing an active constituency with an interest in fighting one or more of the three diseases. The role and function of each player within the partnership of the CCM is agreed upon by joint decision making mechanism, safeguarding equity and transparency among partners. To avoid any real or perceived conflict of interest, organizations or individuals expressed interest in serving as members of the CCM should not benefit from GFATM funding or should declare them in advance during the new membership nomination/selection process.

Roles and responsibilities of VN-CCM Members 
(Governance Manual 2017 – 2019)

Each VN-CCM Member must be willing to accept the following responsibilities:

1. Respect and comply with the Governance Manual, and to other VN-CCM endorsed policy and regulation documents that are referenced in this Governance Manual.
2. Attend and actively participate in VN-CCM meetings.
3. Freely share relevant experiences and information within the meetings.
4. Respect and comply with VN-CCM decisions.
5. Consult regularly with organizations and individuals within their sector and beyond their own individual agency with an aim to fairly and accurately represent their views and concerns at VN-CCM meetings.
6. All CCM members are invited to participate in the process of official decision making of the CCM. The CCM will operate by simple majority vote Individual members represent the interests of their constituency, are responsible for sharing information with their constituents in an open and timely manner, and should hold regular consultations with their constituents to ensure that representative views and concerns are expressed in CCM decisions and meetings.
7. Members should demonstrate neutrality and reaffirm the principle that members of VN-CCM represent a certain constituency and not their respective organizations. More than one member may represent the same constituency.
8. CCM members must openly declare conflicts of interest, and refrain from speaking or voting while the CCM deals with the issue. Once a conflict of interest has been identified, the member may participate in discussions if invited by the Chair or Vice Chair, but may not vote on the related issue. The VN-CCM COU policy is articulated in Section 2, chapter D of this document.
9. Any VN-CCM Member shall have the responsibility to declare a potential conflict of interest concerning any other Member, provided that it is supported by authentic evidence. If the VN-CCM agrees that there is indeed a COI, the Member concerned shall be asked to leave while the issue is being discussed.
10. The role of the United Nations agencies, multilateral and bilateral agencies and other development agencies in the VN-CCM should be country partnership-driven and reflect the roles of these partners in HIV/AIDS, TB, and malaria control in Vietnam.

The roles and responsibilities above shall also apply to Alternate Members.

Rights of VN-CCM Members

Each VN-CCM Member represents the constituents in a particular Sector; while VN-CCM Chair and Vice-Chair are individuals who represent VN-CCM Members. Each CCM Member has the following rights:

1. The right to participate in all discussions and activities of VN-CCM.
2. The right to speak in Vietnamese language during meetings (to be translated/summarized for any international Members not speaking Vietnamese).
3. The right to receive relevant documents in either Vietnamese or English.
4. The right to propose an agenda item for forthcoming CCM meeting.
5. The right to voice an opinion in all matters concerning the mandate of this body prior to decision making.
6. The right to sign, or to decline to sign, proposals submitted by CCM to Global Fund (provided that a CCM Member who declines to sign such a proposal provides clearly articulated reasons, which are recorded in the minutes).
7. The right to vote on any matter that needs to be put to a vote.
8. The right to propose CCM Members for the position of Chair, Vice-Chair, OC members, sub-CCM members or other sub-committee or working group membership
9. The right to receive compensation for travel expenses incurred to attend CCM meetings; when taking part in other CCM activities; or when undertaking assignments for CCM in other parts of the country or overseas, contingent upon VN-CCM receiving adequate funds for this purpose. When and where possible, members should seek other resources to cover these expenses before requesting reimbursement from the VN-CCM.

The rights above shall also apply to Alternates, except for items iv and v, which shall only be exercised in the absence of the Member or if the Member delegates such rights to the Alternate. Item vi applies to Alternates only when they are participating in place of an absent member.

 

Term of Membership

VN-CCM Members and Alternates serve for a term of two (2) years. Upon the expiry of her/his first term, a VN-CCM Member or Alternate may be chosen by her or his sector to serve a further term, and there will be a new selection process at this point.

 

For the term 2020 – 2022, VN-CCM is restructuring the CCM membership and is herewith calling for expression of interest of nominations in the following constituencies:

Sectors	Number of members	Supported by
Vietnam NGOs	2	CCM Sec., VUSTA
People living with HIV/AIDS	1	CCM Sec., VNP+, UNAIDS
People living with Tuberculosis	1	CCM Sec., WHO
People living with Malaria	1	CCM Sec.,  NIMPE
Key Affected Populations	02 (MSM, PWID, SW)	CCM Sec, VUSTA, PEPFAR
FBOs (Religious/Faith-based organizations	1	CCM Sec, Buddhist Singha of Vietnam
Private Sector	1	CCM Sec, VCCI

Organizations/individuals from these constituencies who would like to seek information and get involved in CCM are strongly encouraged to contact CCM Secretariat and facilitator by 28 October 2019.

Elections will be finalized by the end of November 2019.

Phone: (+84) 965927988

Address: Room 706, Level 7, Tower A, D2 Building, Giang Vo, Ba Dinh, Hanoi.

Email: ccmvietnam@gmail.com

On June 19th, 2019 at the Embassy of the French Republic in Vietnam, the meeting on the topic “Perspectives of the Global Fund Replenishment Conference”” took place successfully under the leadership of Mr. Bertrand Lortholary, Ambassador of the French Republic in Vietnam; with the participation of Prof. Dr. Nguyen Thi Kim Tien, Minister of Health of Vietnam and other Ambassadors, Representatives of international organizations in Viet Nam, Delegates and Distinguished guests, Leadership representatives and Specialists of the Ministry of Health in Vietnam.

At the meeting “Perspectives of the Global Fund Replenishment Conference” on June 19th, 2019, Prof. Dr. Nguyen Thi Kim Tien, Minister of Health of Vietnam said:

The Communist Party and Government of Viet Nam always focuses on healthcare, considered that health is the most precious thing of the mankind, and extremely important factor in developing the society and building the economy. So far, the Government has issued many policies, resolutions and documents on healthcare, given priority to investments in resources and techniques for healthcare, whereby the health sector of Viet Nam has achieved many good results.

 

The public health insurance reaches nearly 88% of the population, of which the State provides 100% of health insurance cards for the poor, children under 6 years old, ethnic minorities and some other difficult beneficiaries. Viet Nam strives to cover the health insurance for 100% of the population by 2020. The basic health networkhas covered the whole country. The health system at the commune, district and provincial levels is being reformed comprehensively and synchronously for integration and development. Many commune health stations have also been invested to upgrade and build new ones from the local budgets and aid sources

Viet Nam is highly appreciated by the international community for its successes in achieving the Millennium Development Goals (MDGs). Viet Nam is ranked by the United Nations as one of the top 10 countries in the world to achieve the Millennium Development Goals MDG4 and MDG5 in reducing maternal and child mortality rate, reducing the children malnutrition rate.

Viet Nam is one of the first countries to commit to carry out the United Nations’ goal 90-90-90. Viet Nam has effectively implemented harm reduction and preventions such as syringes and condoms distribution, substitution treatment by Methadone, Buprenorphine, Pre-Exposure Prophylaxis, and community – based testing. 95% of HIV-infected people who have been treated with antiviral drugs reduce the risk of HIV transmission to others. New HIV+ and HIV related deaths has decreased two-thirds in the past 10 years. Viet Nam has been actively coordinating domestic funding including central and local budget, especially Public Health Insurance has been using for HIV/AIDS treatments since 2019. Viet Nam has strongly aimed to end the AIDS epidemic by 2030.

For tuberculosis prevention, in 2019, the multi-drug resistant tuberculosis management coverage rate is more than 70%, the tuberculosis epidemic is decreased by 31% over the past 10 years. Viet Nam has also reached many great achievements, is one of 9 countries to achieve the Millennium Development Goals (MDG) for three indicators of tuberculosis epidemic reduction (new, current tuberculosis disease reduction and death from tuberculosis), is one of the top 3 countries in implementing the WHO tuberculosis termination study (Viet Nam, Brazil and South Africa) and is a pioneer in implementing the Global Tuberculosis Closing Strategy. In 2014, the Prime Minister issued the National Strategy for Tuberculosis Prevention and Control to 2020 with a vision to 2030 in showing the strong political commitment of the Party, State and Ministry of Health for the prevention of tuberculosis.

As the malaria situation in the world and in Viet Nam has been escalating unexpectedly, the increased malaria risk that returns in the coming years, the situation on drug-resistant malaria parasites, chemical-resistant malaria mosquitoes and change in population movement of ethnic minorities and poor people, to strengthen the malaria control measures for protecting the people’s health, the Government of Viet Nam commits to continue to maintain the financial investment in the national malaria prevention targetprogram in the period of 2016-2020 in order to maintain the achievements in malaria control; prevent the risk of increased malaria in causing epidemics affectingthe people’s health and life. Strive to achieve the objectives of the National Strategy for the malaria prevention and elimination in the period of 2011-2020 with an orientation to 2030 approved by the Prime Minister. At the same time call for the aid from international organizations and the Global Fund for the malaria prevention and elimination in Viet Nam in the coming period.

To reach such great achievements, it has a significant contribution through the strict and effective cooperation with developed countries and international organizations. In particular, it is impossible not to refer to the cooperation with the French Republic and the Global Fund, especially in the fight against HIV/AIDS, tuberculosis and malaria. Since 2004, the Global Fund has provided a non-refundable aid to Viet Nam of about 450 million USD for projects on HIV/AIDS, tuberculosis and malaria prevention; of which 50 million USD is the contribution of the French Republic. A budget of 139 million is granted for the period of 2018-2020.

In the coming period, Viet Nam continues to affirm the Government’s strong commitment in the prevention of three diseases and to further enhance the participation of social community organizations and infected people. Viet Nam is also trying to be self-reliant to ensure sustainable results in the prevention of AIDS, tuberculosis and malaria by issuing mechanisms and policies through social insurance and health insurance funds, targeted programs and increase the attraction of resources from the community. However, in the difficult economic and social conditions, the burden of AIDS and tuberculosis is still very high in comparison to the given target. The economic and social barrier to the poor and remote areas, discriminationare still high and needthe active intervention. In order to maintain the achievements of Viet Nam in the last years, Viet Nam wishes to continue cooperating closely with its partners and Global Fund in particular in prevention of three diseases, AIDS, Tuberculosis and Malaria, especially in the next aid round after 2020.

On this occasion, Prof. Dr. Nguyen Thi Kim Tien, Minister of Health of Vietnam would also like to express her deep gratitude to the international partners and organizations that have always supported Viet Nam in the development process in general and in the health development and healthcare in particular.